Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2018-06-30
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure
NCT02718079
Efficacy and Safety of Plasma Exchange Compared to Standard Medical Therapy in Patients With Severe Drug Induced Liver Injury With or Without Underlying Chronic Liver Disease.
NCT04015570
Thromboelastography Guides a Multicentre Cluster Controlled Study of Plasma Exchange for Hepatitis B Associated Acute-on-chronic Liver Failure
NCT04747106
Safety and Efficacy of hiHep Bioartificial Liver Support System to Treat Acute Liver Failure
NCT03084198
High Volume Plasma Exchange in Children With Acute Liver Failure and Acute on Chronic Liver Failure
NCT02719210
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
simple plasma exchange group
The mode is CVVH in CRRT machine, the treatment duration is 2h-3h, the application plasma volume is 40ml/Kg, the replacement fluid flow rate is 1000ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0ml/h.
simple plasma exchange
simple plasma exchange treatment
conventional PDF treatment group
The mode of conventional PDF treatment group is CVVHDF in CRRT machine, and the duration of treatment is 3 hours. the application plasma volume 1500 ml . The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
conventional PDF treatment group
conventional PDF treatment group
less plasma PDF treatment group
The mode of conventional PDF treatment group is also CVVHDF in CRRT machine, and the duration of treatment is 3h. All patients are required to apply plasma 1000ml. Use plasma substitutes: 300ml NS+200ml 5% albumin. The replacement fluid flow rate is 500 ml/h, the dialysate flow rate is 3000 ml/h, the blood flow rate is 100-140 ml/min, and the ultrafiltration volume is 0 ml/h.
less plasma PDF treatment group
less plasma Plasma diafiltration treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
simple plasma exchange
simple plasma exchange treatment
conventional PDF treatment group
conventional PDF treatment group
less plasma PDF treatment group
less plasma Plasma diafiltration treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Model for End-Stage Liver Disease (MELD) \<30 and \>20
* age \> 18 years and \<70years
* Written informed consent
Exclusion Criteria
* allergic to blood products or drugs such as plasma, heparin and protamine
* hemodynamic instability
* cardiovascular and cerebrovascular accidental infarction instability Period
* extravascular hemolysis
* severe sepsis
* Tumor on ultrasonography, CT or MRI examination
* Pregnant or lactating women
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fuzhou General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dongliang Li
professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fuzhou General Hospital, Xiamen Univ
Fuzhou, Fujian, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017L09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.